Figure 1



A
0.001 µg/mL
0.1 µg/mL
100 µg/mL
Doublets 5,89%
Doublets 34,1%
Doublets 0,34%
GEN1046
Doublets 0,62%
Doublets 0,66%
Doublets 0,68%
PD-L1-547-FEALxb12-FEAR +
b12-FEALxCD137-009-HC7LC2-FEAR
CellTrace™ Far Red
CellTrace™ Violet
B
K562_h4-1BB + K562_hPD-L1
% Doublets
40
30
20
10
0
0.001
0.01
0.1
1
10
100
Concentration Ab [µg/mL]
GEN1046
PD-L1-547-FEALxb12-FEAR +
b12-FEALxCD137-009-HC7LC2-FEAR

Figure 2



A. PD1-mediated T cell inhibition
APC or tumor cell
T cell
MHC
TCR
PD1
PD-L1
CD137
B. PD-L1-blockade + T cell co-stimulation
APC or tumor cell
T cell
MHC
TCR
PD1
PD-L1
CD137
CD137xPD-L1 bispecific

Figure 3



A
ES-2 + NFkB-luc2/4-1BB Jurkat
RLU
2.5×10^5
2×10^5
1.5×10^5
1×10^5
5×10^4
0
0.001
0.01
0.1
1
10
100
Concentration Ab [µg/mL]
GEN1046
b12-FEAL
B
MDA-MB-231 + NFkB-luc2/4-1BB Jurkat
RLU
2×10^5
1.5×10^5
1×10^5
5×10^4
0
0.001
0.01
0.1
1
10
100
Concentration Ab [µg/mL]
GEN1046
b12-FEAL

Figure 4



A.
Total T cells
Expansion index
1.8
1.6
1.4
1.2
1.0
0.001
0.01
0.1
1
10
100
Concentration Ab (µg/mL)
GEN1046
PD-L1-547-FEALxb12-FEAR
b12-FEAL
CD3 (0.03 µg/mL)
B.
Total T cells
Expansion index
Concentration GEN1046 (µg/mL)
Central memory T cells
Effector memory T cells
CD3 EM
CD3 CM

Figure 5



1 µg CLDN6
Expansion index
2.5
2.0
1.5
1.0
0.0001
0.001
0.01
0.1
1
Concentration Ab (µg/mL)
GEN1046
w/o PD-1
0.4 µg PD-1
2 µg PD-1
10 µg PD-1
b12-FEAL
w/o PD-1
0.4 µg PD-1
2 µg PD-1
10 µg PD-1

Figure 6



IFN-γ
IFN-γ (pg/mL)
150
100
50
0
0.0001
0.001
0.01
0.1
1
Concentration Ab (µg/mL)
GEN1046
w/o PD-1
2 µg PD-1
b12-FEAL
w/o PD-1
2 µg PD-1
TNF-α
TNF-α (pg/mL)
15
10
5
0
0.0001
0.001
0.01
0.1
1
Concentration Ab (µg/mL)
GEN1046
w/o PD-1
2 µg PD-1
b12-FEAL
w/o PD-1
2 µg PD-1
IL-13
IL-13 (pg/mL)
5
4
3
2
1
0
0.0001
0.001
0.01
0.1
1
Concentration Ab (µg/mL)
GEN1046
w/o PD-1
2 µg PD-1
b12-FEAL
w/o PD-1
2 µg PD-1
IL-8
IL-8 (pg/mL)
300
200
100
0
0.0001
0.001
0.01
0.1
1
Concentration Ab (µg/mL)
GEN1046
w/o PD-1
2 µg PD-1
b12-FEAL
w/o PD-1
2 µg PD-1

Figure 7




A.
All TILs
TIL count per 1,000 beads
10000
1000
100
10
1
*
w/o antibody
0.01 µg/mL
0.1 µg/mL
1 µg/mL
CD137-009-FEALxPD-L1-547-FEAR
B.
CD8+ T cells
CD8+ T cell count per 1,000 beads
10000
1000
100
10
1
*
w/o antibody
0.01 µg/mL
0.1 µg/mL
1 µg/mL
CD137-009-FEALxPD-L1-547-FEAR
C.
CD4+ T cells
CD4+ T cell count per 1,000 beads
10000
1000
100
10
1
w/o antibody
0.01 µg/mL
0.1 µg/mL
1 µg/mL
CD137-009-FEALxPD-L1-547-FEAR
D.
CD56+ NK cells
CD56+ NK cell count per 1,000 beads
10000
1000
100
10
1
*
w/o antibody
0.01 µg/mL
0.1 µg/mL
1 µg/mL
CD137-009-FEALxPD-L1-547-FEAR

Figure 8



DLx: Dose level at which switch from single to 3 patient cohort is conducted
DLy: highest dose level investigated

Figure 9



Best percent change from baseline in tumor size
Colorectal cancer
NSCLC
Ovarian cancer
Pancreatic cancer
Other cancer
Prior PD-(L)1
Best relative change in SoD from baseline (%)
75
50
25
0
-25
-50
-75
Dose level

Figure 10




Best change from baseline in tumor size
Prior PD-(L)1
Best relative change in SoD from baseline (%)
50
25
0
-25
-50
-75
-100
SD
SD
PD
PD
uPR[a]
uPR[a]
140 mg
80 mg
400 mg
50 mg
80 mg
200 mg
PD-L1 TPS, %:[b]
NA
0.5
0
0
30
1
BOR to prior ICI:
PD
CR
PD
SD
PD
PR

Figure 11


A
Best change from baseline in tumor size
Best relative change in SoD from baseline (%)
50
25
0
-25
-50
-75
-100
PD
PD
PD
PD
SD*
SD
SD*
SD*
NE
uPR*[a]
PR*
PR*
PD-L1 TPS, %:[b] 15 0 40 NA 45 85 60* NA 10 80 NA NA
BOR to prior ICI: PR PR PD PD PR PR PD PD NA SD PD NE



B
Target lesion SoD change from baseline
Change in SoD from baseline (%)
50
25
0
-25
-50
-75
-100
0
3
6
9
12
15
18
21
24
Study week
BOR
PD
SD
PR
Time point response
PD
SD
PR
NA

Figure 12




100 mg Q3W
% max average trimer
PDL1 (%)
day
100 mg Q3W
% max average trimer
PDL1 (%)
Over the last (8th) dosage (day)

Figure 13

A


IFNg
p=0.024
100
50
20
10
5
2
1
Fold change from baseline
<=200 mg
(n=37)
>=400 mg
(n=21)

B





IP-10
p=0.009
6
5
4
3
2
1
Fold change from baseline
<=200 mg
(n=36)
>=400 mg
(n=20)

Figure 13

C


Proliferating (KI67+) CD8 T cells
p=0.024
Fold change from baseline
20.0
10.0
5.0
2.0
1.0
0.5
<=200 mg
(n=39)
>=400 mg
(n=22)

D


Proliferating (KI67+) Effector Memory CD8 T cells
p=0.005
Fold change from baseline
20
10
5
2
1
<=200 mg
(n=30)
>=400 mg
(n=21)